ReviewCellular and molecular neurobiology2010
Chromogranin A and the tumor microenvironment.
Review in Cellular and molecular neurobiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- Prognostic significance of Ki-67 in assessing the risk of progression, relapse or metastasis in pheochromocytomas and paragangliomas.Annals of medicine · 2025Article
- Case Report: Postoperative cervical lymph node metastasis of the neuroendocrine carcinoma component of rectal mixed adenoneuroendocrine carcinoma.Frontiers in oncology · 2025Article
- An Overview of Pancreatic Neuroendocrine Tumors and an Update on Endoscopic Techniques for Their Management.Current oncology (Toronto, Ont.) · 2023Review
- Different miRNAs Related toInternational journal of molecular sciences · 2023Article
- Accelerated telomere shortening in adrenal zona reticularis in patients with prolonged critical illness.Frontiers in endocrinology · 2023Article
- Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma.Frontiers in immunology · 2022Article
- Review
- Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation.Annals of the New York Academy of Sciences · 2019Review
- The Morphopathogenetic Aspects of Intraabdominal Adhesions in Children under One Year of Age.Medicina (Kaunas, Lithuania) · 2019Article
- Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights.Frontiers in immunology · 2019Review
- Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.PloS one · 2018Article
- Catestatin as a Target for Treatment of Inflammatory Diseases.Frontiers in immunology · 2018Review
- Chromogranin A Regulation of Obesity and Peripheral Insulin Sensitivity.Frontiers in endocrinology · 2017Review
- Article
- Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models.Oncotarget · 2016Article
- Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Altered chromogranin A circulating levels in Meniere's disease.Disease markers · 2015Article
- Chromogranin A: a paradoxical player in angiogenesis and vascular biology.Cellular and molecular life sciences : CMLS · 2015Review
- Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure.Endocrine connections · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromogranin A (CgA) is an acidic glycoprotein belonging to a family of regulated secretory proteins stored in the dense core granules of the adrenal medulla and of many other neuroendocrine cells and neurons. This protein is frequently used as a diagnostic and prognostic serum marker for a range of neuroendocrine tumors. Circulating CgA is also increased in patients with other diseases, including subpopulations of patients with non-neuroendocrine tumors, with important prognostic implications. A growing body of evidence suggests that CgA is more than a diagnostic/prognostic marker for cancer patients. Indeed, results of in vitro experiments and in vivo studies in animal models suggest that this protein and its fragments can affect several elements of the tumor microenvironment, including fibroblasts and endothelial cells. In this article, recent findings implicating CgA as a modulator of the tumor microenvironment and suggesting that abnormal secretion of CgA could play important roles in tumor progression and response to therapy in cancer patients are reviewed and discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.